| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Canonical SMILES | FC1=C([2H])C([2H])=C(C2=C(/C=C/[C@@H]3C[C@@H](O)CC(O3)=O)C(C4CC4)=NC5=C2C=CC=C5)C([2H])=C1[2H] |
| 分子式 | C25H18D4FNO3 |
| 分子量 | 407.5 |
| 溶解度 | Ethanol: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Pitavastatin lactone-d4is intended for use as an internal standard for the quantification of pitavastatin lactone by GC- or LC-MS. Pitavastatin lactone is a major phase 2 metabolite of the HMG-CoA reductase inhibitor pitavastatin .1,2Pitavastatin lactone is formed when pitavastatin undergoes glucuronidation by the UDP-glucuronysyltransferase (UGT) isoforms UGT1A1, UGT1A3, or UGT2B7 to form pitavastatin glucuronide, which then undergoes non-enzymatic conversion to pitavastatin lactone. It can be retroconverted to pitavastatinviahydrolysis. 1.Fujino, H., Yamada, I., Shimada, S., et al.Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonizationXenobiotica33(1)27-41(2003) 2.Aoki, T., Nishimura, H., Nakagawa, S., et al.Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductaseArzneimittelforschung47(8)904-909(1997) |
m.cnreagent.com